News

“Am I Just Fiddling While Rome Burns?”

Dennis Palumbo, MA, MFT

Crisis Services Struggle to Meet Increased Need Generated From Launch of 988

Artists may struggle with feelings of uselessness in dark times, but here’s why their work is more important than ever.

AD04 for Alcohol Use Disorder: New Positive Results From Pharmacokinetics Study

According to a new study, the launch of 988 did not equate to significant, equitable growth in availability of crisis services.

A Prescription for Loneliness: Mitigating Social Isolation and Loneliness in Older Adults

New positive results of a pharmacokinetics study of AD04 for alcohol use disorder confirms the near micro-dosing regimen planned for upcoming trials.

Temitope Ogundare, MD, MPH

How Experience With Addiction Informs Patient Treatment

How should clinicians approach loneliness in elderly patients, and how can technology assist in treatment?

Christopher L. Schenewerk, MD

No Magic Pill: A Psychiatrist’s Journey Through Grief and Healing

From his own recovery to leading Illinois Recovery Center, Christopher Schenewerk, MD, shares he now champions peer support, naltrexone, and long-term care.

Brittany Albright, MD, MPH

BPL-003 for Alcohol Use Disorder: Positive Topline Results of Phase 2A Study

From dealing with grief to treating a condition, healing can't come with just a magic pill.

Mental Illness Is an Equal Opportunity Employer

Check out new positive topline results from the open-label phase 2A study of BPL-003 in participants with moderate-to-severe alcohol use disorder.

Danielle Egbe, DO;Christina B. Smith, MD

Phase 3 Study Initiated: Osavampator as Adjunctive Therapy for Major Depressive Disorder

How does affluence impact mental health outcomes?

What Time Is It (On the Doomsday Clock)?

Neurocrine is initiating a phase 3 study of osavampator for the treatment of adults with major depressive disorder.

H. Steven Moffic, MD

What Does the Future of Addiction Treatment Look Like?

Let’s set the clock on Doomsday.

Joseph R. Volpicelli, MD, PhD

Label Update for ADHD Treatment Qelbree: New Pharmacodynamic Data and Breastfeeding Information

A transformative shift in addiction treatment and advocating for evidence-based approaches like naltrexone to offer personalized recovery paths beyond traditional abstinence models may be in the future for addiction treatment.

International Holocaust Remembrance Day, the Hostage Exchange, and the Red Cross

According to a new label update, the transfer of Qelbree into breastmilk is low.

H. Steven Moffic, MD

The Prism of Psychiatric Diagnosis

Today is International Holocaust Remembrance Day.

Ronald W. Pies, MD

The Importance of Early Intervention of Addiction and Harm Reduction

Struggling with complex psychiatric diagnoses? Consider the diagnostic prism.

Joseph R. Volpicelli, MD, PhD

The Week in Review: January 20-24

Struggling with alcohol use or concerned about early signs of addiction? Identifying unhealthy drinking patterns early can make a difference.

Megan McSweeney

Demystifying Lithium Therapy—A Primer for Clinicians: Lithium-Related Polyuria, Part 2

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

Jonathan M. Meyer, MD, DLFAPA

In this CME article, learn more about alternative methods to screen for lithium-related polyuria and how to implement amiloride for lithium-related polyuria.

Those Winter Sundays

Richard M. Berlin, MD

Social Psychiatric News Year’s Resolutions #5: Solving our Wicked Problems Dialectically

"What did I know, what did I know of love’s austere and lonely offices?"

H. Steven Moffic, MD

Top 5 Takeaways From the Real Psychiatry Conference

When wicked problems arise, can we defy gravity?